umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder
Show others and affiliations
2017 (English)In: Neurology, ISSN 0028-3878, E-ISSN 1526-632X, Vol. 88, no 10, p. 930-937Article in journal (Refereed) Published
Abstract [en]

Objective: To determine if blood neurofilament light chain (NfL) protein can discriminate between Parkinson disease (PD) and atypical parkinsonian disorders (APD) with equally high diagnostic accuracy as CSF NfL, and can therefore improve the diagnostic workup of parkinsonian disorders. Methods: The study included 3 independent prospective cohorts: the Lund (n 5 278) and London (n 5 117) cohorts, comprising healthy controls and patients with PD, progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), and multiple system atrophy (MSA), as well as an early disease cohort (n 5 109) of patients with PD, PSP, MSA, or CBS with disease duration <= 3 years. Blood NfL concentration was measured using an ultrasensitive single molecule array (Simoa) method, and the diagnostic accuracy to distinguish PD from APD was investigated. Results: We found strong correlations between blood and CSF concentrations of NfL (p >= 0.73-0.84, p <= 0.001). Blood NfL was increased in patients with MSA, PSP, and CBS (i.e., all APD groups) when compared to patients with PD as well as healthy controls in all cohorts (p, 0.001). Furthermore, in the Lund cohort, blood NfL could accurately distinguish PD from APD (area under the curve [AUC] 0.91) with similar results in both the London cohort (AUC 0.85) and the early disease cohort (AUC 0.81). Conclusions: Quantification of blood NfL concentration can be used to distinguish PD from APD. Blood-based NfL might consequently be included in the diagnostic workup of patients with parkinsonian symptoms in both primary care and specialized clinics.

Place, publisher, year, edition, pages
Lippincott Williams & Wilkins, 2017. Vol. 88, no 10, p. 930-937
National Category
Neurology
Identifiers
URN: urn:nbn:se:umu:diva-140250DOI: 10.1212/WNL.0000000000003680ISI: 000397343300008PubMedID: 28179466OAI: oai:DiVA.org:umu-140250DiVA, id: diva2:1149559
Available from: 2017-10-16 Created: 2017-10-16 Last updated: 2018-06-09Bibliographically approved

Open Access in DiVA

fulltext(479 kB)13 downloads
File information
File name FULLTEXT01.pdfFile size 479 kBChecksum SHA-512
204dfe19e51b48fd776d54612bc30b4245599c2b9e65a51c3183c98cbaa07ce2fdd7ae1ef10f2053c6d6b7d2f6db805a31c809cb03c54b8a74326b0d87eedbb1
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Authority records BETA

Linder, JanForsgren, Lars

Search in DiVA

By author/editor
Linder, JanForsgren, Lars
By organisation
Clinical Neuroscience
In the same journal
Neurology
Neurology

Search outside of DiVA

GoogleGoogle Scholar
Total: 13 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 108 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf